NCT06954987View on ClinicalTrials.gov

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

244

Participants

Timeline

Start Date

December 18, 2025

Primary Completion Date

May 15, 2028

Study Completion Date

May 15, 2028

Conditions
Acute Myeloid Leukemia
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Given IV

PROCEDURE

Biospecimen Collection

Undergo blood, urine and buccal swab collection

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

DRUG

Busulfan

Given IV

PROCEDURE

Chest Radiography

Undergo chest x-ray

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Echocardiography Test

Undergo echocardiography

DRUG

Fludarabine

Given IV

DRUG

Melphalan

Given IV

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

Placebo Administration

Given PO

PROCEDURE

Positron Emission Tomography

Undergo PET scan

RADIATION

Total-Body Irradiation

Undergo total body irradiation

DRUG

Venetoclax

Given PO

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH